CSL, U.S. Department of Health and Human Services infectious news

CSL's CSL Biotherapies subsidiary will receive $180 million from HHS under a contract to produce bulk supply of H1N1 influenza vaccine antigen. Last month, HHS announced it would appropriate $1 billion for the development of an H1N1 influenza vaccine, including contracts with AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.), Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) (see BioCentury, May 25). ...